Pharmaxis receives response letter from the FDA on Aridol application
29th
Dec 09
Release Date: 29/12/2009 12:00am
Pharmaxis today announced it had received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) for Aridolâ„¢ (mannitol inhalation powder).
Â
Categories: News and Media